Zobrazeno 1 - 2
of 2
pro vyhledávání: '"S. A. Paciga"'
Autor:
Z. Szekanecz, C. Charles-Schoeman, I. Vranic, B. Sahin, S. A. Paciga, Z. Wang, C. Hyde, D. Martin, J. I. Weitz
Publikováno v:
Annals of the Rheumatic Diseases. 81:179-180
BackgroundIn the ORAL Surveillance study of patients (pts) aged ≥50 yrs with moderate to severe rheumatoid arthritis (RA) and ≥1 additional cardiovascular risk factor (NCT02092467), the incidence of pulmonary embolism was higher with tofacitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec041d2e281f0f30425bc58db2c011be
https://doi.org/10.1136/annrheumdis-2022-eular.787
https://doi.org/10.1136/annrheumdis-2022-eular.787
Autor:
Marwan N. Sabbagh, Holly A. Shill, J. G. Hentz, Erika Driver-Dunckley, Charles H. Adler, John N. Caviness, Lucia I. Sue, Geidy E. Serrano, W. D. Hirst, Ameet C. Patel, Brittany N. Dugger, Thomas G. Beach, Kathryn A. Davis, Ashley R. Winslow, Christine Belden, Sandra Jacobson, S. A. Paciga
Publikováno v:
European journal of neurology, vol 24, iss 11
Background and purpose Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d359aa3874b21f01d1c5c8f34fa6b1
https://europepmc.org/articles/PMC5657539/
https://europepmc.org/articles/PMC5657539/
